InsidersTradesSigma
Follow the Spark Therapeutics, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was disclosed on 4 January 2016 (Cession). Among the most active insiders: Children's Hospital of Philadelphia Foundation. Every trade is free.
Analysts rate Spark Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
1 of 1 declaration
Spark Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapies for rare genetic diseases. It is listed on the NASDAQ under the ticker ONCE.